Trametinib Monotherapy in the Treatment of Pediatric Refractory/Relapse Langerhans Cell Histiocytosis
Pediatric Blood & Cancer · 2026-05 · 73 (5)
DOI: 10.1002/1545-5017.70162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 13.03.2026. Verfasst von Wenqian Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Hauptthemen laut MEDLINE: Histiocytosis, Langerhans-Cell, Pyrimidinones, Pyridones, Salvage Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Chinese Institutes for Medical Research, Beijing.
Abstract (Originalsprache)
Background
Standardized salvage treatments for refractory/relapse Langerhans cell histiocytosis (LCH) remain to be established. Trametinib (TRA) has shown marked efficacy in LCH, but cohort studies regarding efficacy and safety of TRA monotherapy in refractory/relapse LCH were scarce. Methods/Results We retrospectively analyzed 22 patients with refractory/relapse LCH treated with TRA monotherapy. Patients were treated for a median of 21.4 months (3.0–51.6 months). Nineteen (86.4%) of 22 of patients remained progression‐free during TRA treatment. Sixteen patients stopped TRA (not due to progression or toxicity), of which 10 remained progression free, with median follow‐up time of 28.7 months (1.5–44.6 months) after TRA withdrawal, and 6 patients experienced relapse, with median time to relapse from post‐TRA withdrawal of 3.7 months (2.7–16.5 months). Two patients continued on TRA at last follow‐up and one switched to chemotherapy due to toxicity. Three‐year event‐free survival was 50.7% (95% CI: 27.7–69.8), with a median follow‐up time of 36.4 months (3.0–67.6 months). From TRA initiation to 12 months of treatment, cell‐free BRAF/MAP2K1 mutation status in blood presented as negative to negative or positive to negative was correlated with superior event‐free survival rate (EFS) rate. Toxicity was tolerable, and adverse events were predominantly skin rash (77.3%), paronychia (22.7%), and diarrhea (13.6%).
Conclusion
Overall, TRA was effective and safe in the treatment of patients with refractory/relapse LCH, offering a convenient therapeutic alternative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Capital Medical University, Beijing, China.
- Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China.
- Hematologic Disease Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center For Children's Health, Beijing, China.
ORCID-Profile: Yunze Zhao, Tianyou Wang
Förderung
- Chinese Institutes for Medical Research, Beijing
Zitieren
APA
Wang, W., Fang, Z., Ge, J., Zhao, Y., Wang, D., Cui, L., Zhou, C., Li, Z., Wang, T., & Zhang, R. (2026). Trametinib Monotherapy in the Treatment of Pediatric Refractory/Relapse Langerhans Cell Histiocytosis. Pediatric Blood & Cancer, 73(5). https://doi.org/10.1002/1545-5017.70162
Vancouver
Wang W, Fang Z, Ge J, Zhao Y, Wang D, Cui L, et al. Trametinib Monotherapy in the Treatment of Pediatric Refractory/Relapse Langerhans Cell Histiocytosis. Pediatric Blood & Cancer. 2026;73(5). doi:10.1002/1545-5017.70162
BibTeX
@article{Wang2026,
author = {Wang, Wenqian and Fang, Zishi and Ge, Jian and Zhao, Yunze and Wang, Dong and Cui, Lei and Zhou, Chenxin and Li, Zhigang and Wang, Tianyou and Zhang, Rui},
title = {Trametinib Monotherapy in the Treatment of Pediatric Refractory/Relapse Langerhans Cell Histiocytosis},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {5},
doi = {10.1002/1545-5017.70162}
}
EUVIMED